# Trade Mark Journal No.2026/016 17 April 2026

## WO0000001910989 (5,10)

Office of origin: France

Date of International Registration:6 February 2026
Date of designation in the UK: 6 February 2026

International priority date claimed: 27 November 2025 (France) (5203256)

Class 5
  Chemical preparations for medical use, particularly for the diagnosis of cancerous tumors; chemical preparations for medical use for the treatment of cancerous tumors; chemical preparations for medical use for the diagnosis and treatment of tumors using radiotherapy and immunotherapy; chemical preparations comprising nanoparticles for medical use for the diagnosis and treatment of cancerous tumors using radiotherapy; pharmaceutical preparations comprising nanoparticles for the treatment of malignant tumors; radiosensitizing agents for medical use; pharmaceutical compositions for the amplification of radiotherapy; pharmaceutical preparations for the targeted delivery of active ingredients; contrast agents for medical use; products for medical use especially for metabolic pathways; preparation for medical use especially for modifying the bioavailability of therapeutic agents; preparations for medical use especially for modifying liver functions; preparation for medical use for modifying the functions of the reticuloendothelial system; preparation based on nanomaterials for the delivery of therapeutic agents; products for medical use especially for the treatment of brain diseases and disorders; preparation for the diagnosis and treatment of brain diseases and disorders; preparation for medical use particularly for the treatment of Parkinson's disease, Alzheimer's disease, epilepsy and all types of neurological and neuropsychiatric diseases and disorders; preparation for medical use, in particular for treating the symptoms of Parkinson's disease, symptoms of Alzheimer's disease, symptoms of epilepsy and symptoms related to any type of neurological and neuropsychiatric disorders and diseases; preparation for the diagnosis and treatment of neurological disorders and diseases using deep brain stimulation, electrical transcranial stimulation, transcranial direct-current stimulation, transcranial magnetic stimulation, any form of electromagnetic stimulation (light, magnetic field, electric field), radio frequency or ultrasound stimulation; nanoparticles for medical use; chemical reagents for medical use; biological preparations for medical use; enzymes for medical use; chemical preparations for medical or pharmaceutical use; diagnostic products for medical use; drugs for medical use; medicines for human purposes; tonics (medicines); pharmaceutical products.
Class 10
  Medical devices for the diagnosis and treatment of tumors using radiotherapy and immunotherapy; medical devices using nanoparticles for therapeutic or diagnostic purposes; medical devices for the targeted administration of anti-cancer treatments; medical devices for amplifying or optimizing radiotherapy; medical instruments for delivering or activating therapeutic substances; medical devices for combined diagnosis and therapy; medical devices for the diagnosis and treatment of brain diseases and disorders; surgical and medical devices and instruments for deep brain stimulation, electrical transcranial stimulation, transcranial direct-current stimulation, transcranial magnetic stimulation, any form of electromagnetic stimulation (light, magnetic field, electric field), radio frequency or ultrasound stimulation; apparatus for the recording of electrical brain activity (electrodes, electroencephalograph, micro-electrode arrays); apparatus for neuronal modeling.

NANOBIOTIX

Representative: Dreyfus Nathalie DREYFUS & ASSOCIES, 78 avenue Raymond Poincaré, F-75116 PARIS, FRANCE